|
Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, April 01, 2012 ) New York, NY -- Last year was a pivotal year for Coronado Biosciences (CNDO), and with multiple pipeline catalysts set to evolve over the coming months, 2012 is taking shape as a milestone year as well.
Coronado began 2011 as a private company, and after a brief period of trading on the OTC market, the company ended the year on the Nasdaq - without having conducted an IPO. A Form 10 filing with the SEC to convert the company's shares to common stock and become a public company was an unorthodox method of going public, but it did the trick. The quick move to the Nasdaq also ensured that Coronado could appeal to a wider scope of potential investors, as many funds and institutions will not touch a bulletin board stock, and neither will the more conservative of investors.
That said, trading on the Nasdaq also brings with it a responsibility to demonstrate a strength in the pipeline that would compel investors to buy in, and then to stick around as that pipeline developed. Investors will often find themselves asking, "What makes this pipeline or product unique, and what is the potential return should it (they) make it to market?"
Full report is available at the following link: http://vfcsstockhouse.com/blog/article/-coronado-biosciences-cndo-provides-investors-with-two-distinct-pipelines-and-significant-market-potential
Disclosure: No position. VFC's Stock House has received compensation from a third party, TrimRX LLC, to provide research and coverage of Coronado Biosciences for a period of one month. The goal of VFC's Stock House is to bring new ideas, companies and discussions to investors and readers. With respect to the increased amount of time necessary to maintain quality, VFC's Stock House is compensated from third parties to research and cover certain companies that fit the profile of what interests readers of VFC's Stock House. While taking compensation poses as an inherent perception of bias in coverage, the ultimate goal is to bring ideas and information to the eyes of readers, who can then decide what is and what is not relevant. Happy Trading.
Also check out this week's hot stocks to watch, covering Siga Technologies, SiriusXM (SIRI), Advanced Cell Technology (ACTC), Oncothyreon, Cel-Sci Corp and more: http://vfcsstockhouse.com/blog/article/-weekly-news-stock-watch-rimm-fcel-siri-snss-onty-cvm-actc-siga-cndo-ttnp-cpst-bvti-abpi
About VFCsStockHouse.com:
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks and the pharmaceutical and healthcare sectors. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFCÂ’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.
Contact VFC's Stock House: vfc@vfcsstockhouse.com
Originally published at: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
VFC's Stock House
VFC
240-786-2111
vfc@vfcsstockhouse.com 
Source: EmailWire.com
|
|
|
|
